Philadelphia, Pennsylvania, 19148, United States
NCT Number: NCT00820404
Study Evaluating Single Doses of BLI-489 in Healthy Subjects
The purpose of this study is to evaluate the safety, and tolerability of single doses of BLI-489 administered intravenously in healthy subjects, and also how the drug is absorbed and eliminated.
Looking for future studies?
Notify MeKey information
Conditions
Age range
20 year–50 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1
Primary location
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Men or women of nonchildbearing potential, 18 to 50 years of age inclusive at screening.
- Body mass index (BMI) in the range of 18 to 32 kg/m2 and body weight greater than or equal to 50 kg.
- Healthy as determined by the investigator on the basis of the screening evaluations.
- Nonsmoker of smoker of fewer than 10 cigarettes per day as determined by history.
Exclusion criteria
- Presence of history of any disorder that may prevent the successful completion of the study.
- History of drug abuse within 1 year.
Treatment and study plan
BLI-489
DrugPlacebo
DrugPrimary outcomes
-
Safety as measured by the number of adverse events and serious adverse events. Tolerability will be assessed based upon the occurrence of dose limiting toxicities.
Time frame: 15 days
Secondary outcomes
-
Pharmacokinetics as evaluated by drug concentrations in the blood and urine.
Time frame: 4 days
Sponsors and collaborators
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Registry information
Official study title
Ascending Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of BLI-489 Administered Intravenously to Healthy Subjects
Important dates
- Study start
- 2009
- Primary completion
- 2009
- Study completion
- 2009
- First posted
- Jan 12, 2009
- Registry last updated
- Jul 17, 2009
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Bioequivalence (BE) Study Between YHP2511 and YHP2511A in Healthy Volunteers
NCT07470125
Healthy Subjects
Seoul, South Korea
View Trial DetailsAvocado and Postprandial Responses
NCT06818032
Healthy, Healthy Adult
Burlington, Vermont, United States
View Trial DetailsStudy Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years
NCT00761631
Healthy Subjects
Benton, Arkansas, United States
View Trial DetailsHigh Image Matrix CT Reconstruction
NCT02610465
Cardiac-Related Conditions, Healthy Subjects
Bethesda, Maryland, United States
View Trial Details